Laurent Vervueren

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valérie Vilgrain, Héléna Pereira, Eric Assenat et al. · The Lancet Oncology · 2017 · 826 citations

Medicine, Oncology, Radiation Oncology +16

For avid glucose tumors, the SUV peak is the most reliable parameter for [18F]FDG-PET/CT quantification, regardless of acquisition time

Avigaëlle Sher, Franck Lacœuille, Pacôme Fosse et al. · EJNMMI Research · 2016 · 120 citations · Full text

Medicine, Nuclear Medicine, Radiology +17

Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by ¹⁸F-Misonidazole PET/CT in Patients with Non–Small Cell Lung Carcinoma (RTEP5 Study)

Pierre Véra, S. Thureau, Philippe Chaumet‐Riffaud et al. · Journal of Nuclear Medicine · 2017 · 83 citations · Full text

Medicine, Nuclear Medicine, Radiation Oncology +17

Study protocol of the HYPER-LIV01 trial: a multicenter phase II, prospective and randomized study comparing simultaneous portal and hepatic vein embolization to portal vein embolization for hypertrophy of the future liver remnant before major hepatectomy for colo-rectal liver metastases

Emmanuel Deshayes, Lauranne Piron, Antoine Bouvier et al. · BMC Cancer · 2020 · 53 citations · Full text

Medicine, Perioperative Medicine, Surgery +14

Interobserver Agreement of Qualitative Analysis and Tumor Delineation of ¹⁸F-Fluoromisonidazole and 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET Images in Lung Cancer

S. Thureau, Philippe Chaumet‐Riffaud, Romain Modzelewski et al. · Journal of Nuclear Medicine · 2013 · 49 citations · Full text

Medicine, Nuclear Medicine, Radiology +17